Stock listing
SKBBY Stock Price, News, Filings & Events — Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
Selected listing: SKBBY · OTC · USD · US
This page tracks Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H's SKBBY:OTC listing on OTC in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following SKBBY:OTC. SKBBY:OTC is the stock-level entry point for investors researching Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- SKBBY:OTC
- Asset type
- Stock
- Market cap
- $14.95B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- OTC
- Currency
- USD
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H SKBBY:OTC stock context
This page tracks Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H's SKBBY:OTC listing on OTC in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following SKBBY:OTC. SKBBY:OTC is the stock-level entry point for investors researching Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
September 14, 2026
Kelun-Biotech Announces 2026 Interim Results
August 17, 2026
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
July 30, 2026
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
July 27, 2026
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
July 15, 2026
All Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H news →
Research Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H investor report
Review AI stock analysis and investor report context for SKBBY:OTC.
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H company profile
View the public company page for Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H on 6ix.
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H news
Read company news and market updates connected to Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H.
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H investor events
Find investor webinars, events, and replay context for Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H.